Indeed, several agents targeting LKB1 downstream signaling, including AMPK activators, mTOR and COX-2 inhibitors, have been reported to be effective for some cancers, the representatives of which and their effects on cancer cells are listed in Table 2. Here, MTOR is linked to cancer.